More companies worth watching at BIO's Innovation Zone
In our last issue of VOX, we mentioned the impressive list of our NIH portfolio companies who were selected to exhibit and present at BIO’s Innovation Zone. Joining this group in the Innovation Zone is an equally impressive list of 12 portfolio companies from our NSF Phase 1 commercialization assistance program. You've read about one of them, Mango Materials, which was featured in VOX earlier this year.
That makes 31 Larta portfolio companies at this year's BIO Innovation Zone. Check out our list of NSF Phase 1 companies below.
Actuated Medical is a medical device company from Bellefonte, PA that develops medical devices that integrate Innovative Motion and controlled electronics to improve patient outcomes. In Larta’s NSF program they developed Active Needle Technology System (ANTS) - a device available to improve beef and dairy cattle production and care. ANTS vibrates the needle under closed-loop electronic control, resulting in reduced insertion force and less pain/stress to the animal. The system is lightweight, battery operated, ruggedized and low-profile. The Active Needle Technology System (ANTS) reduces insertion force for a 14 gauge needle by 70±5% in large agricultural animals. It accessed hypovolemic and difficult veins with a single stick, reducing the complication rate for repeat sticks or venous cut-down. It also reduce animal pain and subsequent reflexive negative behavioral reactions, as well as reduces tissue scarring that results in lost product in the beef industry.
Arytha BioSciences has developed a tiny nanosponge that can soak up and neutralize bacterial infections by disguising itself as a red blood cell. It works against a wide range of toxins, including those produced by MRSA and E. coli, as well as snake and spider bites. Arytha’s nanosponge also shows promise as a vaccine against the deadly poison created by antibiotic-resistant Staph aureus.
Carmot Therapeutics, Inc. is a small-molecule drug discovery company. Carmot’s technology, Chemotype Evolution, is a pioneering approach to discover drug leads for challenging disease targets. Chemotype Evolution has the potential to be a disruptive technology by applying principles of molecular evolution to small molecule drug discovery. The technique interfaces easily with standard workflows and substantially accelerates the discovery process. Carmot will work with pharmaceutical partners to apply Chemotype Evolution to partners’ targets. Revenue from these partnerships will be used to advance internal programs for high value targets to proof of concept, at which point they will be partnered or sold outright. This model leverages partner revenues to generate internal drug candidates with a high rate of return.
Covaris provides tools and technologies to improve pre-analytical sample preparation, enable novel drug formulations, and manage compounds in the drug discovery process. Founded in 1998, Covaris is a privately held technology company headquartered in Woburn, Massachusetts, USA. The company is built upon its team’s deep knowledge of fields ranging from acoustic physics and mechanical engineering to biophysics and molecular biology and has over 30 patents granted and pending. The Covaris technological foundation is based on its proprietary and patented AFA™ technology. AFA enables a vast array of non-contact, isothermal processes to be developed for use in a broad range of applications in Genomics, Proteomics, Cell Biology and Drug Discovery, and Formulation. Thousands of Focused-ultrasonicators are in use in over 30 countries and customers include the world’s leading researchers, universities, and pharmaceutical companies. Covaris also develops devices and workflow systems to improve the discovery and measurement of molecules and biomarkers in tissue. CryoPrep™, tissueTUBE™ and t-PREP™ enable a tissue samples to be thermally stabilized, reconfigured and chemically stabilized in a system that produces high extraction yields.
CytoMag develops cell separation products for the life sciences research and diagnostics markets. The Company's core technology is a magnetizable capture device that is especially well suited for the capture and release of rare cells.
Extend Biosciences Inc. is an emerging biotechnology company developing a novel drug delivery platform technology that improves the pharmacokinetic properties of peptides and proteins. Peptides have been particularly challenging to bring to market because they are removed from circulation prior to administering therapeutic value. Our proprietary platform technology significantly improves the circulating half-life and bioavailability of peptides and proteins, enabling the scientific community to truly develop potent and specific drugs.
LambdaVision, Inc. is commercializing a retinal implant to restore vision for the millions of patients suffering from retinitis pigmentosa (RP) and age-related macular degeneration (AMD). Both RP and AMD lead to the loss of photoreceptor cells, and the retinal implant developed by LambdaVision is inserted behind the retina to replace the function of these damaged cells.
Lignolink is commercializing a patented technology for genetic modification of crops to improve digestibility through modification of the lignocellulosic structure. The technology has potential benefits for biofuels feedstock and livestock forages. The company develops and demonstrates the technology in various plants, and will partner with established ag biotech companies for product commercialization.
Mango Materials produces biodegradable, biobased plastic pellets from methane gas. Waste methane gas (such as biogas from a wastewater treatment plant) can be used and bacteria are employed to transform this potent greenhouse gas into a valuable product. The polymer produced is polyhydroxyalkanoate (PHA), and these plastic pellets can be converted into a variety of products such as molded and extruded plastic goods (electronic casings, packaging, consumer products, etc). The plastics that are produced are not only derived from rapidly renewable waste resources but are also completely biodegradable when they are disposed.
Nanofiber Separations, LLC produces functionalized nanofiber mats for separations applications in the (bio) pharmaceutical, wastewater treatment, blood products, biorenewable products, and similar industries. The unique features of the separation media allow process to be completed faster, cheaper, and with less process intrusion than alternative operations.
Nimbic Systems, Inc. is a medical device company located outside of Houston, Texas. Founded in 2007, the Company started with the vision to create devices to protect patients during surgery. Their latest technology, the Air Barrier System (ABS), is cleared by the US Food and Drug Administration for use in hip and posterior spine surgery.
TeraPore Technologies, Inc. is developing cutting edge membrane technology for high-permeability, high-resolution separations needs.